Felix Blanc-Durand, MD, Institut Gustave Roussy, Villejuif, France, discusses the significant potential of liquid biopsy in patients with advanced cancer. He emphasizes that while most gynecological cancers are diagnosed at a localized stage and might not exhibit circulating tumor DNA (ctDNA), liquid biopsies become more effective for advanced disease cases. In advanced endometrial cancer, over 90% of patients were found to have detectable ctDNA, which can classify patients into four molecular subgroups and identify targetable alterations. Dr Blanc-Durand highlights that in the era of personalized medicine, ctDNA holds a privileged position, and its importance is likely to grow in the coming years. This interview took place at the ESMO Gynaecological Cancers Congress 2024 in Florence, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть